Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer.

about

Synthetic nanoparticles for delivery of radioisotopes and radiosensitizers in cancer therapy

P2860

Q28066010-CD803C18-C60F-4212-958F-EF519716F230

P2860

Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer.

Item

http://www.wikidata.org/entity/Q36451556

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Beta emitters rhenium-188 and ...... experimental cervical cancer.

@ast

Beta emitters rhenium-188 and ...... experimental cervical cancer.

@en

type

Item

label

Beta emitters rhenium-188 and ...... experimental cervical cancer.

@ast

Beta emitters rhenium-188 and ...... experimental cervical cancer.

@en

prefLabel

Beta emitters rhenium-188 and ...... experimental cervical cancer.

@ast

Beta emitters rhenium-188 and ...... experimental cervical cancer.

@en

P1476

Beta emitters rhenium-188 and ...... experimental cervical cancer.

@en

P2093

Darrell R Fisher

http://www.w3.org/2001/XMLSchema#string

Ekaterina Dadachova

http://www.w3.org/2001/XMLSchema#string

Ekaterina Revskaya

http://www.w3.org/2001/XMLSchema#string

Gary L Goldberg

http://www.w3.org/2001/XMLSchema#string

Rebecca Phaeton

http://www.w3.org/2001/XMLSchema#string

Zewei Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Treating cancer as an infectious disease--viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology

177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.

The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in mice

T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.

Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line

Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6.

Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer.

Management of recurrent cervical cancer.

Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma

Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein.

P304

9-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.562

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26625938

http://www.w3.org/2001/XMLSchema#string

P932

4708900

http://www.w3.org/2001/XMLSchema#string

Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer.

about

P2860

P2860

Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932